The Impact of Renal Function on Liver Cirrhosis among Patients in Wasit Governorate, Iraq

Article Sidebar

PDF
Published: Sep 6, 2023
DOI: https://doi.org/10.47191/ijmscrs/v3-i9-08
Keywords:
Renal Function on Liver CirrhosisWasit Governorate

Main Article Content

Fatima Saad Abdalzahraa
Alqasim Green University, College Of Biotechnology – Babylon – Iraq
Estabraq Lafta Muhsen
Alqasim Green University, College Of Biotechnology – Babylon – Iraq
Rwnaq Naseer Mahmood
Alqasim Green University, College Of Biotechnology – Babylon – Iraq
Ayat Naeem Sakal
Alqasim Green University, College Of Biotechnology – Babylon – Iraq
Samah Faleh Shnawa
Alqasim Green University, College Of Biotechnology – Babylon – Iraq
Hassan Saad Thijeel
Biomedical Engineering University of Technology – Bagdad – Iraq

Abstract

In Al-Kut city's AL-Zahraa general hospital, this study was carried out.for individuals with liver cirrhosis to evaluate their serum levels of ALT, AST, GGT, ALP, urea, creatinine, T.Protien, Albumin, and Bilirubin. The 50 patients ranged in age from 20 to 60, with 29 male and 21 female individuals.Based on the patient's medical history and physical examination, liver cirrhosis was determined to affect both sexes of the patient.   The 30 control groups were drawn from the medical personnel and family of those who did not exhibit any indications or symptoms of renal liver disease or kidney diseases. With ages ranging from 22 to 66, there were 20 men and 10 women. Eight to fourteen hours following the patients' overnight fasts, blood samples were obtained. The research reveals the following.


Serum ALT, AST and GGT concentrations in liver cirrhosis patients were found to be significantly increased compared with control group (P<0.01).Serum Bilirubin (Total) and direct Bilirubin concentrations in liver cirrhosis patients were found to be significantly high compared with control group (P<0.5), (P<0.01) respectively. Serum Albumin concentrations in liver cirrhosis patients were found to be no significantly lower compared with control group (P>0.5). Serum Total protein concentrations in liver cirrhosis patients were found to be no significantly lower compared with control group (P≤0.5).Serum Alkaline phosphatase (ALP) concentrations in liver cirrhosis patients were found to be significantly increased compared with control group (P<0.01).Serum urea, creatinine, Uric acid and ammonia level concentrations in  liver cirrhosis patients were found to be significantly high compared with control group (P<0.01).

Article Details

How to Cite
Abdalzahraa, F. S. ., Estabraq Lafta Muhsen, Rwnaq Naseer Mahmood, Ayat Naeem Sakal, Samah Faleh Shnawa, & Hassan Saad Thijeel. (2023). The Impact of Renal Function on Liver Cirrhosis among Patients in Wasit Governorate, Iraq. International Journal of Medical Science and Clinical Research Studies, 3(9), 1835–1839. https://doi.org/10.47191/ijmscrs/v3-i9-08
Issue
Vol. 3 No. 9 (2023): Volume 03 Issue 09 September 2023
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Reintam Blaser, A., Preiser, J. C., Fruhwald, S., Wilmer, A., Wernerman, J., Benstoem, C., ... & Deane, A. M. (2020). Gastrointestinal dysfunction in the critically ill: a systematic scoping review and research agenda proposed by the Section of Metabolism, Endocrinology and Nutrition of the European Society of Intensive Care Medicine. Critical care, 24, 1-17.

II. Muscate, F., Woestemeier, A., & Gagliani, N. (2021, August). Functional heterogeneity of CD4+ T cells in liver inflammation. In Seminars in Immunopathology (Vol. 43, No. 4, pp. 549-561). Berlin/Heidelberg: Springer Berlin Heidelberg.

III. Zhou, W. C., Zhang, Q. B., & Qiao, L. (2014). Pathogenesis of liver cirrhosis. World journal of gastroenterology: WJG, 20(23), 7312.4- Tsochatzis, E. A., Bosch, J., & Burroughs, A. K. (2014). Liver cirrhosis. The Lancet, 383(9930), 1749-1761.

IV. Zakeri, N., & Tsochatzis, E. A. (2017). Bleeding risk with invasive procedures in patients with cirrhosis and coagulopathy. Current Gastroenterology Reports, 19, 1-9.

V. Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. D. O., Berti, E., ... & Xiao, W. (2022). The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia, 36(7), 1720-1748.

VI. Millward-Sadler GH. Cirrhosis: an appraisal. Liver and biliary disease. 1985:821-60.

VII. Chouhan, M. D., Lythgoe, M. F., Mookerjee, R. P., & Taylor, S. A. (2016). Vascular assessment of liver disease—towards a new frontier in MRI. The British journal of radiology, 89(1064), 20150675.

VIII. Health, United States, 2006 with chartbook on trends in the health of Americans. No. 2006. National Center for Health Statistics, 2007.

IX. Mendizabal, M., Piñero, F., Ridruejo, E., Wolff, F. H., Anders, M., Reggiardo, V., ... & Research, L. A. L. (2020). Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents. Clinical Gastroenterology and Hepatology, 18(11), 2554-2563..

X. Andriulli, A., Stroffolini, T., Mariano, A., Valvano, M. R., Grattagliano, I., Ippolito, A. M., ... & Rizzetto, M. (2018). Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas. European Journal of Internal Medicine, 53, 79-84.

XI. Boyle, M., Masson, S., & Anstee, Q. M. (2018). The bidirectional impacts of alcohol consumption and the metabolic syndrome: cofactors for progressive fatty liver disease. Journal of hepatology, 68(2), 251-267.

XII. Shi, Y., Wang, Q., Sun, Y., Zhao, X., Kong, Y., Ou, X., ... & You, H. (2020). The prevalence of lean/nonobese nonalcoholic fatty liver disease: a systematic review and meta-analysis. Journal of clinical gastroenterology, 54(4), 378-387.

XIII. Tian, Y., Feng, H., Han, L., Wu, L., Lv, H., Shen, B., ... & Liu, G. (2018). Magnolol alleviates inflammatory responses and lipid accumulation by AMP-activated protein kinase-dependent peroxisome proliferator-activated receptor α activation. Frontiers in immunology, 9, 147.

XIV. Conn, H.; Atterbury, C. Cirrhosis. In: Schiff, L.; Schiff, E., editors. Diseases of the Liver. 7th edition. Lippencott Company, Philadelphia; Philadelphia: 1993. p. 875-934.

XV. Verslype, C. (2004). Evaluation of abnormal liver-enzyme results in asymptomatic patients. Acta Clinica Belgica, 59(5), 285-289.

XVI. Targher, G. (2010). Elevated serum γ-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer–a narrative review. Clinical Chemistry and Laboratory Medicine, 48(2), 147-157.

XVII. Whitfield, J. B., Zhu, G., Nestler, J. E., Heath, A. C., & Martin, N. G. (2002). Genetic covariation between serum γ-glutamyltransferase activity and cardiovascular risk factors. Clinical chemistry, 48(9), 1426-1431.

XVIII. Gerbes, A.L., 2016. Liver cirrhosis and kidney. Digestive Diseases, 34(4), pp.387-390.

XIX. Allegretti, A. S., Ortiz, G., Cui, J., Wenger, J., Bhan, I., Chung, R. T., ... & Irani, Z. (2016). Changes in kidney function after transjugular intrahepatic portosystemic shunts versus large-volume paracentesis in cirrhosis: a matched cohort analysis. American Journal of Kidney Diseases, 68(3), 381-391.

XX. Appenrodt, B., & Lammert, F. (2018). Renal failure in patients with liver cirrhosis: novel classifications, biomarkers, treatment. Visceral medicine, 34(4), 246-252.

XXI. Sabolić, I., Asif, A. R., Budach, W. E., Wanke, C., Bahn, A., & Burckhardt, G. (2007). Gender differences in kidney function. Pflügers Archiv-European Journal of Physiology, 455, 397-429.

XXII. Rosenthal, P., Pincus, M., & Fink, D. (1984). Sex-and age-related differences in bilirubin concentrations in serum. Clinical chemistry, 30(8), 1380-1382.

XXIII. MeraJR, D. B., & Feldman, M. (2008). Influence of gender on the ratio of AST and ALT in patients without hyperbilirubinemias. Dig Dis Sci, 53, 799-802.

XXIV. Adiga, U. (2016). Gender differences in liver function tests in Coastal Karnataka. IOSR Journal of Dental andMedical Sciences, 15(8), 30-32.

XXV. Alam, S. F., Kumar, S., & Ganguly, P. (2019). Measurement of homocysteine: a historical perspective. Journal of clinical biochemistry and nutrition, 65(3), 171-177.

XXVI. Paprotny, Ł., Wianowska, D., Izdebska, M., Celejewska, A., Szewczak, D., & Solski, J. (2020). Analysis of serum homocysteine in the laboratory practice-comparison of the direct chemiluminescence immunoassay and high performance liquid chromatography coupled with fluorescent detection. Biochemia Medica, 30(3), 439-445.

XXVII. Fissell, R. B., Bragg-Gresham, J. L., Woods, J. D., Jadoul, M., Gillespie, B., Hedderwick, S. A., ... & Young, E. W. (2004). Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney international, 65(6), 2335-2342.

XXVIII. Adane, T., & Getawa, S. (2021). The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis. PloS one, 16(6), e0251570.

XXIX. Bajaj, J. S., Moreau, R., Kamath, P. S., Vargas, H. E., Arroyo, V., Reddy, K. R., ... & Wong, F. (2018). Acute‐on‐chronic liver failure: getting ready for prime time?. Hepatology, 68(4), 1621-1632.

XXX. Qaddoori, H., hassan, A., Al-shoky, M., K. Kalil, Y., & Mudhafar, M. (2022). Comparative study of Some biochemical and Immunological parameters of patients with COVID-19 disease and non-infected people. Egyptian Journal of Chemistry, 65(10), 217-223. doi: 10.21608/ejchem.2022.113854.5172